FDA approves new lung cancer diagnostic tool, intraveneous opioid

Aug 10, 2020 - 03:00 PM
FDA product update

The Food and Drug Administration Friday approved the first liquid biopsy companion diagnostic that uses next-generation sequencing technology to identify patients with specific gene mutations in a deadly form of metastatic non-small cell lung cancer.

“In addition to benefitting from less invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to decreased wait times for starting treatment and provide insight into possible resistance mechanisms,” said Tim Stenzel, M.D., director of FDA’s Office of In Vitro Diagnostics and Radiological Health.

In other news, the agency Friday approved a new intraveneous opioid for managing acute pain in adults in hospital and other controlled clinical settings, such as inpatient and outpatient procedures. The drug, Olinvyk (oliceridine), has a maximum recommended daily dose limit of 27 milligrams.

Related News Articles

Headline
FDA issues early alert for heart pump controllers following 3 deaths, dozens of injuries 
The Food and Drug Administration has issued an early alert for all automated Impella controllers by Abiomed following an issue that has caused three deaths and…
Headline
Medical device supplier says cyber incident is disrupting some operations
Boston Scientific, a large supplier of medical devices, said in an Aug. 26 statement posted on its website that on Aug. 25 it “identified a cybersecurity…
Headline
FDA issues alert for certain Medline convenience kits 
The Food and Drug Administration has issued an early alert for specific lots of BD ChloraPrep Applicators by Medline because of a potential breach of sterility…
Headline
FDA recalls certain first aid kits with TRUE METRIX blood glucose devices 
The Food and Drug Administration has identified a Class I recall of North American Rescue first aid kits containing TRUE METRIX Blood Glucose Monitoring…
Headline
FDA says shortage of breast biopsy needles expected to last until 2027 
The Food and Drug Administration June 16 announced that a nationwide shortage of stereotactic breast biopsy needles is expected to last through the end of…
Blog
Sutter Health strengthens maternal care through innovation and connection
High-quality maternal care is essential to protecting the health of both mom and baby during birth.Sutter Health is taking a proactive, systemwide approach to…